Executive Summary Over the past decade, antibody–drug conjugates (ADCs) have become one of the most important therapeutic platforms in oncology drug development. Several ADCs have achieved major clinical success, particularly in breast cancer, hematologic malignancies, and emerging solid tumor indications. However, early generations of ADCs were still constrained by important limitations, including: reliance on a single payload mechanism dependence on a single tumor antigen